149 related articles for article (PubMed ID: 38025187)
1. Histomorphological and Immunohistochemical Study of Dacomitinib-Induced Ileal Mucositis in Rats with the Possible Protection by Baicalin.
Kandeel S; Estfanous RS
J Microsc Ultrastruct; 2023; 11(3):135-144. PubMed ID: 38025187
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
Van Sebille YZA; Gibson RJ; Wardill HR; Secombe KR; Ball IA; Keefe DMK; Finnie JW; Bowen JM
Int J Cancer; 2017 Jun; 140(12):2820-2829. PubMed ID: 28316082
[TBL] [Abstract][Full Text] [Related]
3. [Protective effect of baicalin against LPS-induced intestinal injury].
Wu Q; Ye H; Zhu YZ; Guo M; He XX; Zheng XB
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(17):2854-8. PubMed ID: 24380310
[TBL] [Abstract][Full Text] [Related]
4. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
Van Sebille YZA; Gibson RJ; Wardill HR; Ball IA; Keefe DMK; Bowen JM
Int J Cancer; 2018 Jan; 142(2):369-380. PubMed ID: 28921512
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
6. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Kim DW; Garon EB; Jatoi A; Keefe DM; Lacouture ME; Sonis S; Gernhardt D; Wang T; Giri N; Doherty JP; Nadanaciva S; O'Connell J; Sbar E; Cho BC
Lung Cancer; 2017 Apr; 106():76-82. PubMed ID: 28285698
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.
Xu L; Wu H; Jiang C; Wang H; Gao B; Yan S; Qi Y; Zhou S
Discov Med; 2016 Nov; 22(122):297-309. PubMed ID: 28009971
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
9. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
[TBL] [Abstract][Full Text] [Related]
10. ERK Signaling Pathway Plays a Key Role in Baicalin Protection Against Acetaminophen-Induced Liver Injury.
Liao CC; Day YJ; Lee HC; Liou JT; Chou AH; Liu FC
Am J Chin Med; 2017; 45(1):105-121. PubMed ID: 28081632
[TBL] [Abstract][Full Text] [Related]
11. Effects of dacomitinib on the pharmacokinetics of poziotinib
Ji W; Shen J; Wang B; Chen F; Meng D; Wang S; Dai D; Zhou Y; Wang C; Zhou Q
Pharm Biol; 2021 Dec; 59(1):457-464. PubMed ID: 33899675
[TBL] [Abstract][Full Text] [Related]
12. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.
Lacouture ME; Keefe DM; Sonis S; Jatoi A; Gernhardt D; Wang T; Doherty JP; Giri N; Nadanaciva S; O'Connell J; Sbar E; Piperdi B; Garon EB
Ann Oncol; 2016 Sep; 27(9):1712-8. PubMed ID: 27287210
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
14. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension.
Yu X; Zhao X; Zhang J; Li Y; Sheng P; Ma C; Zhang L; Hao X; Zheng X; Xing Y; Qiao H; Qu L; Zhu D
Eur J Pharmacol; 2019 May; 850():97-108. PubMed ID: 30753867
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Tanaka H; Sakamoto H; Akita T; Ohyanagi F; Kawashima Y; Tambo Y; Tanimoto A; Horiike A; Miyauchi E; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
Thorac Cancer; 2022 May; 13(10):1471-1478. PubMed ID: 35415873
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
[TBL] [Abstract][Full Text] [Related]
18. Baicalin, silver titanate, Bletilla striata polysaccharide and carboxymethyl chitosan in a porous sponge dressing for burn wound healing.
Gong YR; Zhang C; Xiang X; Wang ZB; Wang YQ; Su YH; Zhang HQ
J Integr Med; 2023 Sep; 21(5):487-495. PubMed ID: 37544834
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Ramalingam SS; Jänne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CB; Goldberg Z; O'Connell J; Paz-Ares L
Lancet Oncol; 2014 Nov; 15(12):1369-78. PubMed ID: 25439691
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.
Calvo E; Soria JC; Ma WW; Wang T; Bahleda R; Tolcher AW; Gernhardt D; O'Connell J; Millham R; Giri N; Wick MJ; Adjei AA; Hidalgo M
Clin Cancer Res; 2017 Mar; 23(5):1177-1185. PubMed ID: 27733479
[No Abstract] [Full Text] [Related]
[Next] [New Search]